Collegium Pharmaceutical Inc (NASDAQ:COLL)

18.17
Delayed Data
As of Jul 01
 +0.45 / +2.54%
Today’s Change
14.04
Today|||52-Week Range
25.63
-2.73%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$619.7M

Company Description

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Contact Information

Collegium Pharmaceutical, Inc.
100 Technology Center Drive
Stoughton Massachusetts 02072
P:(781) 713-3699
Investor Relations:

Employees

Shareholders

Mutual fund holders58.39%
Other institutional48.93%
Individual stakeholders20.96%

Top Executives

Joseph J. CiaffoniPresident, Chief Executive Officer & Director
Colleen TupperChief Financial Officer & Executive Vice President
Scott SudduthExecutive Vice President-Technical Operations
Thomas B. SmithChief Medical Officer & Executive Vice President
Scott DreyerChief Commercial Officer & Executive VP